Abstract
Interleukin-1β (IL-1β) is a powerful pro-inflammatory cytokine synthesized in the inflammasome complex of immune cells in response to injury and infection. The excess activity of this cytokine plays a fundamental role in the pathogenesis of the autoinflammatory disorders. An emphasis on pediatric rheumatology is given to systemic-onset juvenile idiopathic arthritis (SoJIA) and periodic fever syndromes. Until the last decade, there wasnt an efficient alternative for the treatment of autoinflammatory syndromes refractory for convencional therapies. This scenery was modified with the introduction of biological agents, especially the IL-1 antagonist group (Anakinra, Rilonacept and Canakinumab). Canakinumab, a fully human anti-IL-1β monoclonal antibody, selectively binds to IL-1β, and intercepts the spread of inflammation. This medication was approved for treatment of cryopyrin-associated periodic syndrome (CAPS) in 2009, and SoJIA in 2013, and has shown to be an excellent tool for controlling these disorders.
Highlights
Interleukin-1b (IL-1b) is a powerful pro-inflammatory cytokine synthesized in the inflammasome complex of immune cells in response to injury and infection
Canakinumab, a fully human anti-IL-1b monoclonal antibody, selectively binds to IL-1b, and intercepts the spread of inflammation. This medication was approved for treatment of cryopyrinassociated periodic syndrome (CAPS) in 2009, and systemiconset juvenile idiopathic arthritis (SoJIA) in 2013, and has shown to be an excellent tool for controlling these disorders
Patients with arthritis (SoJIA and pediatric granulomatous arthritis) received a subcutaneous dose of 4mg/kg every 4 weeks, whereas patients with periodic fever syndromes received a subcutaneous dose of 2mg/kg every
Summary
Interleukin-1b (IL-1b) is a powerful pro-inflammatory cytokine synthesized in the inflammasome complex of immune cells in response to injury and infection. The excess activity of this cytokine plays a fundamental role in the pathogenesis of the autoinflammatory disorders. There wasnt an efficient alternative for the treatment of autoinflammatory syndromes refractory for convencional therapies. This scenery was modified with the introduction of biological agents, especially the IL-1 antagonist group (Anakinra, Rilonacept and Canakinumab). Canakinumab, a fully human anti-IL-1b monoclonal antibody, selectively binds to IL-1b, and intercepts the spread of inflammation. This medication was approved for treatment of cryopyrinassociated periodic syndrome (CAPS) in 2009, and SoJIA in 2013, and has shown to be an excellent tool for controlling these disorders
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
